Global HPV Associated Disorders Market

Global HPV Associated Disorders Market Size, Trends & Analysis - Forecasts to 2026 By Indication (Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Acute Interstitial Nephritis (AIN), Anal Cancer, Genital Warts and Others), By Therapy (Prevention, Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on November 16 2024 with the latest and most recent market numbers

HPV Associated Disorders Market Insights

The human papillomavirus (HPV) is an extremely prevalent viral infection that can be passed between people via direct skin-to-skin contact. Approximately more than 100 variants of human papillomavirus are present and around 40% of these variants can be transmitted through sexual contact between sexually active men & women and affects genitalia parts due to direct genital contact which also infects the individual’s reproductory tracts. HPV infection includes cervical cancer, anogenital warts, vulvar cancer, anogenital cancer, oropharyngeal cancers, and respiratory papillomatosis. A large proportion of human papillomavirus infections do not cause any problems and automatically get clear within a few months of getting infected without any medication or therapeutics. But around 14 types of HPV are considered a risky type or carcinogenic. Therefore, with the growing number of HPV-associated ailments, there is an expanding demand in the market for proper treatment procedures to cure HPV infections at the early stage.

Cervical cancer occurs due to the prolonged presence of human papillomavirus infection and mostly occurs in women. Cervical cancer comes in the fourth position of most frequent gynecological cancer and is among the top 10 leading causes of cancer-associated death in the women population worldwide. As per the World Health Organization, over 570,000 novel cases of cervical cancer were registered in 2018. Around 311,000 deaths are caused due to cervical cancer and more than 1/3 rd of the deaths occur in low and middle-income economies. Therefore, there is a proliferating emphasis on the prevention of cervical cancer in women through awareness programs related to HPV infections and growing vaccination procedures for girls to protect against human papillomavirus, and thereby, all of these will give a boost to the market growth.

Increasing government emphasis and expenditure on preventing HPV-associated diseases by conducting vaccination procedures and expanding spending on research activities related to HPV-associated disorders like cervical cancer, anal cancer, cervical intraepithelial neoplasia, and genital warts will augment the overall market growth. Moreover, WHO has taken up the initiative and formulated a global strategy to eradicate HPV-associated cancerous disorders like cervical cancer by the end of the year 2030. This strategy states that 90% of girls (below 15 years of age) should be HPV vaccinated, 70% of middle-aged women (35-45 years of age) should be screened with advanced tests and 90% of the women diagnosed with HPV cancerous disease should get treatment. Therefore, these aforementioned factors will address the promising future of the market throughout the forecast period.

Nevertheless, the restraining aspects such as lower consumer awareness regarding HPV-associated disorders and increasing adverse effects of the treatment will hamper the HPV-associated disorders market growth. However, the major market drivers like the growing incidence of HPV-associated disorders, rising number of cervical cancer patients and mortality rate, growing WHO & government level initiatives for HPV prevention, growing spending on oncology research, and increasing usage for HPV infection therapeutics & preventive vaccines will eventually create a hostile environment for the growth of HPV-associated disorders market. These contributing factors will propel the HPV-associated disorder’s market growth throughout the forecast period.

global hpv associated disorders market

HPV Associated Disorders Market: By Indication

Based on the indications, the market is categorized into cervical intraepithelial neoplasia (CIN), cervical cancer, acute interstitial nephritis (AIN), anal cancer, genital warts, and others. The cervical cancer indication segment will lead in this market segment. This is due to the growing usage of bevacizumab (Avastin) as a targeted therapy for cervical cancer and increasing cases of patients suffering from this cancer. CIN is a condition that occurs before cervical cancer and the persistent presence of CIN can progress to cervical cancer and, therefore, the CIN segment will witness the fastest growth rate.

HPV Associated Disorders Market: By Therapy

Based on the therapy, the human papillomavirus-associated disorder market is segmented into prevention and treatment. The preventive therapy segment will have the largest market share due to increasing government and WHO emphasis on vaccine procedures related to HPV-associated diseases. The commercially available vaccines are Gardasil and Cervarix. Moreover, vigilant actions and policies to conduct cancer research projects and expanded support for cancer prevention through enhanced funding are likely to help this market segment to expand significantly.

HPV Associated Disorders Market: By Distribution Channel

Based on the distribution channel, the market is classified as hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment will be accountable for the largest share in the market due to increasing investment in developing strong healthcare facilities and an enlarging stockpile of treatment products for HPV-associated disorders. The online pharmacy segment will grow at a faster rate due to increasing consumer emphasis on doorstep delivery and the presence of discounts on product prices.

asia pacific hpv associated disorders market

HPV Associated Disorders Market: By Region

As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central South America (Brazil, Argentina, and Rest of Central and South America). The North American region will dominate the HPV-associated disorders market throughout the forecast period due to growing expenditure on healthcare and the advancing government initiatives for vaccination procedures related to HPV. All through the forecast period, Asia Pacific is expected to record the highest CAGR. Rapid economic prosperity, investments in healthcare facilities, a rise in discretionary income, and an uptick in customer consciousness are all set to lead to regional growth.

HPV Associated Disorders Market Share and Competitor Analysis

Merck & Co Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca plc, Biocon Ltd., GlaxoSmithKline plc, Allergan plc, Eli Lilly and Company, Cytovation AS, and Advaxis are the key players in the HPV associated disorders market.

Please note: This is not an exhaustive list of companies profiled in the report.

In December 2020, AstraZeneca plc acquired the Alexion pharmaceuticals company for its rare disease therapies and state-of-the-art pipeline for rare diseases with greater production facilities in biologics. This has helped AstraZeneca plc to penetrate the new geographical region with a greater hold in immunology and expand its product portfolio and pipeline.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview And Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 HPV Associated Disorders Industry Overview, 2019-2026

2.1.1 Industry Overview

2.1.2 Indication Overview

2.1.3 Therapy Overview

2.1.4 Distribution Channel Overview

2.1.5 Regional Overview

Chapter 3 HPV Associated Disorders Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2019-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Growing incidence of HPV associated disorders

3.3.1.2 Increasing number of cervical cancer patients and mortality rate

3.3.1.3 Growing WHO and government level initiatives for HPV prevention

3.3.1.4 Growing spending on oncology research

3.3.1.5 Increasing usage for HPV infection therapeutics and preventive vaccines

3.3.2 Industry Challenges

3.3.2.1 Lower consumer awareness regarding HPV associated disorders

3.3.2.2 Increasing adverse effects of the treatment

3.4 Prospective Growth Scenario

3.4.1 Indication Growth Scenario

3.4.2 Therapy Growth Scenario

3.4.3 Distribution Channel Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Technology Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 HPV Associated Disorders Market, By Indication

4.1 Indication Outlook

4.2 Cervical Intraepithelial Neoplasia (CIN)

4.2.1 Market Size, By Region, 2019-2026 (USD Million)

4.3 Cervical Cancer

4.3.1 Market Size, By Region, 2019-2026 (USD Million)

4.4 Acute Interstitial Nephritis (AIN)

4.4.1 Market Size, By Region, 2019-2026 (USD Million)

4.5 Anal Cancer

4.5.1 Market Size, By Region, 2019-2026 (USD Million)

4.6 Genital Warts

4.6.1 Market Size, By Region, 2019-2026 (USD Million)

4.7 Others

4.7.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 5 HPV Associated Disorders Market, By Therapy

5.1 Therapy Outlook

5.2 Prevention

5.2.1 Market Size, By Region, 2019-2026 (USD Million)

5.3 Treatment

5.3.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 6 HPV Associated Disorders Market, By Distribution Channel

6.1 Distribution Channel Outlook

6.2 Hospital Pharmacies

6.2.1 Market Size, By Region, 2019-2026 (USD Million)

6.3 Retail Pharmacies

6.3.1 Market Size, By Region, 2019-2026 (USD Million)

6.4 Online Pharmacies

6.4.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 7 HPV Associated Disorders Market, By Region

7.1 Regional outlook

7.2 North America

7.2.1 Market Size, By Country 2019-2026 (USD Million)

7.2.2 Market Size, By Indication, 2019-2026 (USD Million)

7.2.3 Market Size, By Therapy, 2019-2026 (USD Million)

7.2.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.2.5 U.S.

7.2.5.1 Market Size, By Indication, 2019-2026 (USD Million)

7.2.5.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.2.5.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.2.6 Canada

7.2.6.1 Market Size, By Indication, 2019-2026 (USD Million)

7.2.6.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.2.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.3 Europe

7.3.1 Market Size, By Country 2019-2026 (USD Million)

7.3.2 Market Size, By Indication, 2019-2026 (USD Million)

7.3.3 Market Size, By Therapy, 2019-2026 (USD Million)

7.3.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.3.5 Germany

7.3.5.1 Market Size, By Indication, 2019-2026 (USD Million)

7.3.5.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.3.5.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.3.6 UK

7.3.6.1 Market Size, By Indication, 2019-2026 (USD Million)

7.3.6.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.3.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.3.7 France

7.3.7.1 Market Size, By Indication, 2019-2026 (USD Million)

7.3.7.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.3.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.3.8 Italy

7.3.8.1 Market Size, By Indication, 2019-2026 (USD Million)

7.3.8.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.3.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.3.9 Spain

7.3.9.1 Market Size, By Indication, 2019-2026 (USD Million)

7.3.9.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.3.9.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.3.10 Russia

7.3.10.1 Market Size, By Indication, 2019-2026 (USD Million)

7.3.10.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.3.10.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.4 Asia Pacific

7.4.1 Market Size, By Country 2019-2026 (USD Million)

7.4.2 Market Size, By Indication, 2019-2026 (USD Million)

7.4.3 Market Size, By Therapy, 2019-2026 (USD Million)

7.4.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.4.5 China

7.4.5.1 Market Size, By Indication, 2019-2026 (USD Million)

7.4.5.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.4.5.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.4.6 India

7.4.6.1 Market Size, By Indication, 2019-2026 (USD Million)

7.4.6.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.4.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.4.7 Japan

7.4.7.1 Market Size, By Indication, 2019-2026 (USD Million)

7.4.7.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.4.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.4.8 Australia

7.4.8.1 Market Size, By Indication, 2019-2026 (USD Million)

7.4.8.2 Market size, By Therapy, 2019-2026 (USD Million)

7.4.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.4.9 South Korea

7.4.9.1 Market Size, By Indication, 2019-2026 (USD Million)

7.4.9.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.4.9.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.5 Latin America

7.5.1 Market Size, By Country 2019-2026 (USD Million)

7.5.2 Market Size, By Indication, 2019-2026 (USD Million)

7.5.3 Market Size, By Therapy, 2019-2026 (USD Million)

7.5.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.5.5 Brazil

7.5.5.1 Market Size, By Indication, 2019-2026 (USD Million)

7.5.5.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.5.5.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.5.6 Mexico

7.5.6.1 Market Size, By Indication, 2019-2026 (USD Million)

7.5.6.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.5.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.5.7 Argentina

7.5.7.1 Market Size, By Indication, 2019-2026 (USD Million)

7.5.7.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.5.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.6 MEA

7.6.1 Market Size, By Country 2019-2026 (USD Million)

7.6.2 Market Size, By Indication, 2019-2026 (USD Million)

7.6.3 Market Size, By Therapy, 2019-2026 (USD Million)

7.6.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.6.5 Saudi Arabia

7.6.5.1 Market Size, By Indication, 2019-2026 (USD Million)

7.6.5.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.6.5.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.6.6 UAE

7.6.6.1 Market Size, By Indication, 2019-2026 (USD Million)

7.6.6.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.6.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

7.6.7 South Africa

7.6.7.1 Market Size, By Indication, 2019-2026 (USD Million)

7.6.7.2 Market Size, By Therapy, 2019-2026 (USD Million)

7.6.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

Chapter 8 Company Landscape

8.1 Competitive Analysis, 2020

8.2 Merck & Co Inc

8.2.1 Company Overview

8.2.2 Financial Analysis

8.2.3 Strategic Positioning

8.2.4 Info Graphic Analysis

8.3 Pfizer Inc

8.3.1 Company Overview

8.3.2 Financial Analysis

8.3.3 Strategic Positioning

8.3.4 Info Graphic Analysis

8.4 F. Hoffmann-La Roche Ltd

8.4.1 Company Overview

8.4.2 Financial Analysis

8.4.3 Strategic Positioning

8.4.4 Info Graphic Analysis

8.5 AstraZeneca plc

8.5.1 Company Overview

8.5.2 Financial Analysis

8.5.3 Strategic Positioning

8.5.4 Info Graphic Analysis

8.6 Biocon Ltd

8.6.1 Company Overview

8.6.2 Financial Analysis

8.6.3 Strategic Positioning

8.6.4 Info Graphic Analysis

8.7 GlaxoSmithKline plc

8.7.1 Company Overview

8.7.2 Financial Analysis

8.7.3 Strategic Positioning

8.7.4 Info Graphic Analysis

8.8 Allergan plc

8.8.1 Company Overview

8.8.2 Financial Analysis

8.8.3 Strategic Positioning

8.8.4 Info Graphic Analysis

8.9 Eli Lilly and Company

8.9.1 Company Overview

8.9.2 Financial Analysis

8.9.3 Strategic Positioning

8.9.4 Info Graphic Analysis

8.10 Cytovation AS

8.10.1 Company Overview

8.10.2 Financial Analysis

8.10.3 Strategic Positioning

8.10.4 Info Graphic Analysis

8.11 Advaxis

8.11.1 Company Overview

8.11.2 Financial Analysis

8.11.3 Strategic Positioning

8.11.4 Info Graphic Analysis

The Global HPV Associated Disorders Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the HPV Associated Disorders Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.